ArticlePloS one2026
Similarity of sputum mediator signatures between e-cigarette users and COPD depends on GOLD stage and type of e-cigarette: a pilot study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is overlap in symptoms and airway pathobiology between COPD and e-cigarette (e-cig) users. We sought to determine if young adult e-cig users have similar sputum soluble mediator profiles to COPD and if this is related to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage and generation of e-cig device. Experimental groups (n = 20-30/group) included non-smokers, smokers at risk of COPD ("pre-COPD"), mild/moderate COPD (GOLD 1/2), and severe COPD (GOLD 3) from the SPIROMICS cohort and healthy e-cig users of 3rd and 4th generation devices (previously published). Sputum soluble mediator profiles were compared between COPD GOLD stages and then between e-cig users of both generation devices and COPD participants by GOLD stage using a suite of computational approaches, including correlation analyses, unsupervised machine learning, and multivariate distance metrics. Inflammatory mediators were significantly increased in pre-COPD and GOLD 3 versus non-smokers and GOLD 1/2. Soluble mediator profiles of e-cig users showed patterns of overlap with COPD that were GOLD stage specific and based on shared biological functions that included proteases (MMP9, MMP2) and elastases (neutrophil elastase, myeloperoxidase). These findings indicate similarities in soluble mediator profiles between e-cig users and patients with COPD, highlighting potentially similar biological mechanisms relating to inflammation and tissue remodeling. Future studies with younger COPD cohorts, and those with preserved ratio impaired spirometry (PRISm) or bronchitis versus apical emphysema are needed to fully understand the extent of biological mechanisms that are shared between e-cig users and COPD. This pilot study represents a first step in understanding potential similarities between mediator changes in the airways of COPD patients and otherwise healthy young adult e-cig users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.